Ellipta critical error studies - COPD
Significantly fewer patients using Ellipta made critical errors compared with other commonly used inhalers, after reading the patient information leaflet. 1
A critical error is defined as inhaler usage likely to result in no, or minimal, medication being inhaled. The key results were:
- 8 x fewer patients made critical errors with Ellipta compared to Accuhaler
- 5 x fewer patients made critical errors with Ellipta compared to MDI
- 3 x fewer patients made critical errors with Ellipta compared to Handihaler
MDI, metered dose inhaler
Ellipta, Accuhaler and the shape of the respective inhalers are registered trademarks of the GSK group of companies. Other trademarks referred to herein are the property of their respective owners.
- All participants were receiving treatment and were naïve to using the Ellipta inhaler and at least one of the other five inhaler devices of comparison: Accuhaler, MDI, Turbohaler, HandiHaler and Breezhaler.
- Participants received inactive treatment (placebo) via the Ellipta inhaler and one of the five other inhaler devices depending on the study to which they were allocated.
- Patients were randomised to determine the sequence in which they demonstrated inhaler use.
- At the study visit, participants were asked to demonstrate use of the inhaler after reading the patient information leaflet; any errors made were recorded by a study nurse using a specific checklist for each inhaler.
- The primary endpoint was the percentage of participants making at least one critical error after reading the patient information leaflet.
The Ellipta Critical Errors data has been published in the NPJ – PCRM (Nature Partners Journal – Primary Care Respiratory Medicine).
Visit our COPD page to learn more about our medicines which are part of the Ellipta portfolio.